Citizens Financial Group Inc. RI Acquires 3,600 Shares of Eli Lilly and Company $LLY

Citizens Financial Group Inc. RI lifted its holdings in Eli Lilly and Company (NYSE:LLY) by 5.1% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 74,287 shares of the company’s stock after buying an additional 3,600 shares during the quarter. Eli Lilly and Company comprises 0.8% of Citizens Financial Group Inc. RI’s portfolio, making the stock its 26th biggest holding. Citizens Financial Group Inc. RI’s holdings in Eli Lilly and Company were worth $56,680,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in LLY. Sumitomo Mitsui Financial Group Inc. acquired a new stake in shares of Eli Lilly and Company in the second quarter valued at approximately $27,000. Evolution Wealth Management Inc. bought a new position in Eli Lilly and Company in the 2nd quarter valued at $29,000. Steph & Co. increased its stake in shares of Eli Lilly and Company by 290.0% in the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after buying an additional 29 shares during the period. Financial Gravity Companies Inc. acquired a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at $31,000. Finally, Bare Financial Services Inc raised its position in shares of Eli Lilly and Company by 263.6% during the second quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock worth $31,000 after acquiring an additional 29 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 1.6%

Shares of NYSE:LLY opened at $1,080.92 on Tuesday. The company has a 50 day moving average price of $1,040.85 and a two-hundred day moving average price of $863.67. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. The company has a market capitalization of $1.02 trillion, a PE ratio of 52.88, a PEG ratio of 0.77 and a beta of 0.35. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The company had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. During the same quarter in the previous year, the business earned $1.18 EPS. The firm’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Analyst Ratings Changes

LLY has been the topic of several recent research reports. Weiss Ratings reiterated a “buy (b-)” rating on shares of Eli Lilly and Company in a report on Monday, December 22nd. Zacks Research upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 1st. The Goldman Sachs Group lifted their price target on shares of Eli Lilly and Company from $951.00 to $1,145.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Cantor Fitzgerald reissued an “overweight” rating on shares of Eli Lilly and Company in a research note on Monday, December 1st. Finally, UBS Group began coverage on shares of Eli Lilly and Company in a research note on Tuesday, January 6th. They issued a “buy” rating and a $1,250.00 price objective on the stock. Five equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $1,169.00.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Nvidia partnership — Lilly and Nvidia will fund a San Francisco Bay Area co‑innovation AI lab with up to $1 billion committed over five years to accelerate AI‑driven drug discovery; the deal boosts Lilly’s AI capabilities and signal‑markets view it as a major productivity/innovation catalyst. Nvidia, Eli Lilly to spend $1 billion over five years on joint research lab
• Positive Sentiment: Ventyx acquisition — Markets reacted positively to Lilly’s deal for Ventyx Biosciences (inflammation‑focused assets that could complement Lilly’s GLP‑1 franchise), which investors interpret as strategic bolt‑on M&A that expands weight‑loss program adjacencies and clinical upside. Eli Lilly Stock Broke Out Following Plan To Acquire Ventyx Biosciences
• Positive Sentiment: Manufacturing expansion — Lilly’s large Houston manufacturing project (multi‑billion dollar plant) supports production capacity for growing drug volumes and reduces supply risk, a positive for long‑term revenue visibility. Texas seals Eli Lilly’s plans for $7B manufacturing plant in Houston biotech hub
• Positive Sentiment: Supply reassurance for orforglipron — Lilly said it’s confident in supply ahead of expected U.S. approval for its oral weight‑loss candidate, reducing near‑term execution risk around a potential major launch. Lilly says it’s confident weight-loss pill supply ahead of U.S. approval
• Neutral Sentiment: Aktis/AKTS exposure and other biotech bets — Lilly’s equity and collaboration investments (e.g., Aktis) signal diversified R&D exposure but remain speculative and will only move LLY materially if programs hit milestones.
• Neutral Sentiment: Analyst commentary & price forecasts — Several outlets reiterated growth narratives and long‑term forecasts (Zacks, Motley Fool, 24/7 Wall St. pieces), supporting investor sentiment but not immediate fundamentals.
• Negative Sentiment: Competition from Novo Nordisk’s Wegovy pill — The launch of an oral Wegovy competitor increases market competition in the oral weight‑loss category and was earlier cited as the key near‑term headwind that pressured LLY shares. (Market reaction has been mixed as investors weigh competition vs. Lilly’s pipeline and M&A.)

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.